Louie Pasculli

New research examining the prevalence of chronic traumatic encephalopathy among former NFL players provides additional insight into CTE pathology, while highlighting the challenges of interpreting findings from postmortem brain-donation studies.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent reductions in brain amyloid in adults with early Alzheimer disease, although development of the agent was discontinued before dose expansion because of sponsor business considerations.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

Findings from a phase 1 study showed that bilateral putaminal delivery of AAV2-GDNF using convection-enhanced delivery was well tolerated over 5 years, although exploratory clinical measures did not demonstrate significant improvements from baseline.

Cellenkos’ investigational allogeneic, cord blood-derived T-regulatory cell therapy is being evaluated in a phase 1/1b study in ALS, with early findings showing reductions in plasma neurofilament light chain and increases in IL-10.

The FDA has granted De Novo Authorization to Avulux's optical-filter lenses to reduce light sensitivity in patients aged 12 years or older with episodic migraine.

Erika Trovato, DO, MS, program director of the Brain Injury Medicine Fellowship at Burke Rehabilitation Hospital, provided clinical advice for trainees and early-career physicians looking to establish themselves in the field.

The designation for the investigational brain-penetrant IDH1 inhibitor comes as the pivotal phase 3 SIGMA study evaluates its use in patients with high-risk IDH1-mutant astrocytoma.

The FDA extended its review of deramiocel for Duchenne muscular dystrophy to November 22, 2026, after accepting additional HOPE-3 data.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Huntington disease!

New prespecified MINT analysis found that inebilizumab reduced exacerbations and rescue therapy use compared with placebo in adults with AChR- or MuSK-positive generalized myasthenia gravis.

Kyle Marden, MD, sports neurologist and medical director of the Concussion and Sports Neurology Program at Northwestern Medicine, discusses emerging developments in concussion diagnosis and management, ongoing challenges in the field, and the future of individualized care.

A narrative review highlighted the limited pediatric-specific evidence supporting headache treatment after stroke and in cerebrovascular disorders, emphasizing consideration of vascular pathophysiology, cerebral perfusion, and collateral flow when selecting therapies.

The FDA granted Fast Track designation to Acadia Pharmaceuticals’ investigational remlifanserin for hallucinations and delusions associated with Alzheimer disease psychosis.

A recently published case study highlights a 17-year-old patient with Duchenne muscular dystrophy who experienced acute and delayed cardiac toxic effects under delandistrogene moxeparvovec treatment, with tissue analyses showing low-level, heterogeneous microdystrophin expression.

Stacey Tarrant, RD, LDN, discusses how earlier treatment alongside disease-modifying therapies have changed nutritional priorities in spinal muscular atrophy, including the need to optimize growth, strength, function, and body composition.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is acute ischemic stroke!

Experimental small molecule CN045 promoted oligodendrocyte maturation and modest remyelination in preclinical models of multiple sclerosis, supporting further development of the compound as a potential remyelination therapy.

Voyager Therapeutics is advancing 2 tau-targeted Alzheimer disease therapies toward key clinical milestones expected in the fourth quarter of 2026, including tau PET imaging data for VY7523 and first-in-human dosing for VY1706.

Uma Menon, MD, Adult Neurology Residency Program Director at Allina Health Brain and Spine Institute, shares lessons on navigating fellowship, finding the right career path, building expertise, and maintaining balance throughout a career in neurology.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Spinal Muscular Atrophy!

Topline findings from the Phase 2 SUNRISE-PD study showed statistically significant improvements in clinical measures, inflammatory biomarkers, and exploratory neurodegeneration markers among patients with early Parkinson disease treated with bezisterim.

New phase 1 data showed favorable pharmacokinetic and safety findings for the investigational orexin-2 receptor agonist BP-205, supporting continued clinical development.

Neurologist Takaomi Saido, PhD, discusses decades of research into the neprilysin-donanemab and amyloid-beta–tau axes in Alzheimer disease, highlighting potential mechanisms underlying the transition from amyloid to tau pathology and opportunities to develop earlier, more targeted disease-modifying therapies.

Elizabeth Ferluga, MD, and Kristen Fortino discuss a newly launched virtual care program, the barriers facing patients with ataxia, and the potential for remote access to specialized care to improve diagnosis, treatment, and clinical trial connectivity.

As research expands beyond amyloid and tau, experts discuss how novel biomarkers could identify multiple coexisting neurodegenerative pathologies and pave the way for more personalized treatment approaches based on each patient’s unique disease profile. [WATCH TIME: 9 Minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is chronobiology in neurology!

As research moves toward treating Alzheimer disease before symptoms emerge, experts highlight the potential of plasma biomarkers to identify at-risk individuals, guide clinical trial enrollment, and create a window for intervention before irreversible neuronal damage occurs. [WATCH TIME: 6 Mintes]

Updated phase 2 data showed durable responses and sustained disease control with safusidenib after nearly 40 months of follow-up, prompting plans for phase 3 and phase 2 studies in newly diagnosed and post-vorasidenib IDH1-mutant glioma.